// App-Quantinova.ai

P47.17 : Capmatinib vs Docetaxel in Pretreated Patients With MET Exon 14 Skipping–mutated Stage IIIB/IIIC or IV NSCLC (GeoMETry-III)

Researchers

Presenter

  • P. Souquet

Principal Investigators

  • S. Kim

  • B. Solomon

  • J. Vansteenkiste

  • S. Glaser

  • J. Wolf

Medical Centers

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Department 1 for Internal Medicine, Center for Integrated Oncology Koln-Bonn, University Hospital Cologne, Cologne, Germany

  • University Hospital of Lyon-Sud, Lyon/FR

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Peter Maccallum Cancer Centre, Melbourne/VIC/AU

  • University Hospital Ku Leuven, Leuven/BE

  • Novartis Pharma Ag, Basel/CH

Locations

  • France

  • United States

  • Belgium

  • Switzerland

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain metastasis

  • Solid malignancies

  • Non Small Cell Lung cancer

Biomarkers

  • C-Type Lectin Domain Containing 11A

  • Epidermal growth factor receptor

Drug/Treatment

  • Capmatinib

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Cross Over

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • NCT02414139

  • NCT04427072

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved